APRI (Aprinoia Therapeutics) Shares Buyback Ratio %: 3.85 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Shares Buyback Ratio %?

Aprinoia Therapeutics APRI Shares Buyback Ratio % is 3.85 as of Aug. 02, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Aprinoia Therapeutics's current shares buyback ratio was 3.85%.

Aprinoia Therapeutics Shares Buyback Ratio % Related Terms

Aprinoia Therapeutics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Shares Buyback Ratio % Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Shares Buyback Ratio %
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Shares Buyback Ratio % 0.00 0.00 0.00 0.00 3.85

Aprinoia Therapeutics Shares Buyback Ratio % Calculation

Aprinoia Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(27.937 - 27.937) / 27.937
=0.00%

Aprinoia Therapeutics's Shares Buyback Ratio for the quarter that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Jun. 2023 )
=(27.937 - 26.861) / 27.937
=3.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 3.85 mean?
Aprinoia Therapeutics (APRI) has a Shares Buyback Ratio % of 3.85 as of Aug. 02, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Shares Buyback Ratio % too high?
Aprinoia Therapeutics' current Shares Buyback Ratio % is 3.85.
How does Aprinoia Therapeutics' Shares Buyback Ratio % compare to ?
Aprinoia Therapeutics' Shares Buyback Ratio % of 3.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Shares Buyback Ratio % is 3.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Shares Buyback Ratio % of 3.85. The current Shares Buyback Ratio % is 3.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Shares Buyback Ratio % is 3.85 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.